Sam Altman's longevity startup is upping the dose in an Alzheimer's drug trial after a lackluster first round
- Alzheimer 近 90 天出现 2 次
- 上一次：2 天前 · FDA clears blood test to aid evaluation for Alzheimer's disease
发生了什么
The Sam Altman-backed longevity biotech company is upping the dose of its experimental Alzheimer's drug in clinical trials.
摘要按规则整理自下方来源原文